XML 26 R10.htm IDEA: XBRL DOCUMENT

Other Current Assets	12 Months Ended
Other Current Assets	Dec. 31, 2020
Other Current Assets
Other Current Assets	4.Other Current Assets As of December 31, 2020, other current assets included prepaid expenses of $0.9 million, comprised primarily of prepayments of $0.6 million made for the Company’s clinical trials for BP1002 in lymphoma and prexigebersen-A in solid tumors as well as prepaid insurance of $0.3 million. As of December 31, 2019, other current assets included prepaid expenses of $0.8 million, comprised primarily of prepayments made for the Company’s clinical trial for prexigebersen in AML of $0.6 million and prepaid insurance of $0.2 million.